Clinical trial
A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
NCT06959641 is registered in ClinicalTrials.gov with Jochen Lorch as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
- Lead sponsor
- Jochen Lorch
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 6, 2025
- Completion date
- September 11, 2030
- Enrollment
- 33 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced differentiated thyroid gland carcinoma, locally advanced poorly differentiated thyroid gland carcinoma, locally advanced thyroid gland follicular carcinoma, locally advanced thyroid gland oncocytic carcinoma, locally advanced thyroid gland papillary carcinoma, metastatic differentiated thyroid gland carcinoma, metastatic poorly differentiated thyroid gland carcinoma, metastatic thyroid gland follicular carcinoma, metastatic thyroid gland oncocytic carcinoma, metastatic thyroid gland papillary carcinoma, refractory differentiated thyroid gland carcinoma, refractory poorly differentiated thyroid gland carcinoma, refractory thyroid gland follicular carcinoma, refractory thyroid gland oncocytic carcinoma, refractory thyroid gland papillary carcinoma, stage iii differentiated thyroid gland carcinoma ajcc v8, stage iii thyroid gland follicular carcinoma ajcc v8, stage iii thyroid gland papillary carcinoma ajcc v8, stage iv differentiated thyroid gland carcinoma ajcc v8, stage iv thyroid gland follicular carcinoma ajcc v8, stage iv thyroid gland papillary carcinoma ajcc v8